Teladoc Health scheduled next results. USD 606.93 million tests Teladoc Health stock

Published on 10/18/2026 at 13:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue fell 4.00 percent year over year to USD 606.93 million. Teladoc Health stock enters the October 28 results test.

Upcoming results and operating pressure

Teladoc Health announced on October 14, 2026, that third-quarter results will arrive on October 28, 2026.
Second-quarter revenue fell 4.00 percent year over year to USD 606.93 million.
Teladoc Health had a USD 1.0 billion market capitalization and a USD 4.40 to USD 9.89 52-week range as of October 16, 2026.

TDOC, US87918A1051, Illustration mit AI erstellt.

Teladoc Health (ISIN US87918A1051) scheduled its third-quarter results for October 28, 2026, according to Nasdaq. The date gives investors a defined checkpoint after second-quarter revenue fell 4.00 percent year over year to USD 606.93 million.

Three events shape the story

On September 11, 2026, Chief Executive Officer Charles Divita sold 17,805 shares for USD 108,681, according to Investing.com. On October 7, 2026, Teladoc Health introduced SoloVitals and SoloScribe, with Solo installed in more than 15,000 care locations, according to Yahoo Finance. On October 14, 2026, the company announced the October 28 results date through Nasdaq.

What will October 28 test?

The upcoming report will show whether Teladoc can offset weaker revenue with product adoption and cost control. In the second quarter of 2026, revenue was USD 606.93 million, operating profit was negative USD 37.09 million, and net income was negative USD 38.91 million. The figures indicate that the revenue decline was accompanied by continuing operating and bottom-line losses.

MarketBeat reported on October 14, 2026, that 16 brokerages had a consensus Hold rating and an average 12-month target of USD 7.54. The same report said second-quarter adjusted earnings per share were a loss of USD 0.21 against a consensus loss of USD 0.25, while revenue missed the USD 615.44 million estimate.

Dates and valuation markers

Teladoc Health's next substantiated reporting date is October 28, 2026, when third-quarter results are due after the market closes, according to Nasdaq.

Market value frames the test

Teladoc Health had a USD 1.0 billion market capitalization on October 16, 2026. Its 52-week range was USD 4.40 to USD 9.89, leaving the forthcoming report to address both shrinking revenue and the company's ability to turn its connected-care products into broader commercial momentum. The further course of trading is shown by the continuously updated real-time quote of Teladoc Health stock.